| Literature DB >> 35172723 |
Mohammad Hosein Yazdanpanah1,2, Mohammad Mehdi Naghizadeh1, Sepideh Sayyadipoor3, Mojtaba Farjam4.
Abstract
BACKGROUND: QT interval as an indicator of ventricular repolarization is a clinically important parameter on an electrocardiogram (ECG). QT prolongation predisposes individuals to different ventricular arrhythmias and sudden cardiac death. The current study aimed to identify the best heart rate corrected QT interval for a non-hospitalized Iranian population based on cardiovascular mortality.Entities:
Keywords: Iran; QT correction formula; QT interval; QTc prolongation; Survival
Mesh:
Year: 2022 PMID: 35172723 PMCID: PMC8851728 DOI: 10.1186/s12872-022-02502-2
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Different QT correction formulas
| Corrections | Formulas |
|---|---|
| Exponential | |
| Bazett [ | QTcB = QT/RR0.50 |
| Fridericia [ | QTcFri = QT/RR0.333 |
| Dmitrienko [ | QTcD = QT/RR0.413 |
| Linear | |
| Framingham [ | QTcFra = QT + 0.154 (1-RR) |
| Hodges [ | QTcH = QT + 0.00175 (HR-60) |
| Rautaharju [ | QTcR = QT − 0.185 (RR-1) + ka |
QT QT interval (ms), RR RR interval (ms), HR heart rate (bpm)
ak = + 6 ms for men and + 0 ms for women
Baseline characteristics of subjects according to gender
| Variables | Male | Female | |
|---|---|---|---|
| Age (years) | 48.49 ± 9.28 | 48.69 ± 9.40 | 0.367a |
| Heart rate (bpm) | 65.99 ± 10.87 | 75.16 ± 11.59 | |
| QRS duration (ms) | 98.50 ± 10.70 | 95.46 ± 9.90 | |
| QT interval (ms) | 403.82 ± 36.32 | 395.63 ± 37.19 | |
| QTcB (ms) | 420.24 ± 31.91 | 439.63 ± 33.58 | |
| QTcFri (ms) | 414.40 ± 29.57 | 424.05 ± 32.63 | |
| QTcFra (ms) | 414.09 ± 29.14 | 423.83 ± 30.36 | |
| QTcH (ms) | 414.30 ± 29.33 | 422.16 ± 29.92 | |
| QTcR (ms) | 422.16 ± 29.75 | 429.40 ± 31.05 | |
| QTcD (ms) | 417.14 ± 30.18 | 431.46 ± 32.15 | |
| All-cause mortality | 46 (1.5) | 33 (0.8) | |
| Cardiac mortality | 26 (0.8) | 19 (0.5) | 0.053 |
| Survival days+ | 1154.27 ± 115.23 | 1172.65 ± 107.32 | |
| Subjects with mortality | 600.08 ± 312.08 | 655.51 ± 346.86 | |
| Subjects without mortality | 1162.68 ± 85.45 | 1176.96 ± 91.61 | |
| Selected medications† | 691 (22.4) | 1124 (28.1) | |
| CVD history | 302 (9.8) | 557 (13.9) | |
| Stroke | 40 (1.3) | 52 (1.3) | 0.992 |
| CHD | 274 (8.9) | 522 (13.1) | |
| MI | 77 (2.5) | 52 (1.3) | |
| Medical conditions | 617 (20.0) | 1773 (44.4) | |
| Diabetes | 251 (8.2) | 638 (16.0) | |
| Hypertension | 354 (11.5) | 1083 (27.1) | |
| Renal failure | 35 (1.1) | 33 (0.8) | 0.184 |
| Chronic lung disease | 50 (1.6) | 85 (2.1) | 0.124 |
| Hepatitis | 3 (0.1) | 0 (0.0) | |
| Thyroid dysfunction | 76 (2.5) | 563 (14.1) |
Data are reported as mean ± standard deviation or as count (percentages). p value reported as the result of aIndependent sample t and bChi-square tests. Statistically significant p values are bolded (p value < 0.05)
bpm beats per minute, QTc corrected QT interval, Bazett’s correction formula (QTcB), Fridericia’s correction formula (QTcFri), Dmitrienko’s correction formula (QTcD), Framingham’s correction formula (QTcFra), Hodges’s correction formula (QTcH), Rautaharju’s correction formula (QTcR), ms milliseconds
+Survival days calculated from the day of electrocardiogram recording until their last follow-up in Fasa PERSIAN cohort Study
†Selected medications is a list of drugs with known and possible risks for Torsade de Pointes, which accounted for 187 cardiac and non-cardiac drugs in total [35]
Determination of the best qt correction formula based on previously published equations
| QT correction model | Description | QT correction formula | R2 | |
|---|---|---|---|---|
| Similar to Framingham Heart study [ | Linear regression model | QTc1 = QT + 0.155 * RR − 0.009 * Gender | 0.347 | |
| Similar to Hodges study [ | Linear regression model | QTc2 = QT + 0.176 * RR | 0.343 | |
| Similar to Spence et al. [ | Linear regression model after logarithmic transformation | Female | QTc3 = QT/RR**0.365 | 0.346 |
| Male | QTc3 = QT/RR**0.333 | 0.376 | ||
| Similar to Wernicke et al. [ | Finding zero correlation between QTc and RR | QTc4 = QT/RR**0.316 | – | |
QT QT interval (s), RR RR interval (s)
Determination of the lowest beta coefficient to find the best correction formula among previously published formulas by linear regression analysis of QTc and RR according to both genders
| QTc formulas | B for RR | 95% CI | Constant (ms) | 95% CI (ms) | R2 |
|---|---|---|---|---|---|
| Male | |||||
| QTcB | − 0.073 | − 0.080 to − 0.066 | 488.42 | 481.79 to 495.058 | 0.119 |
| QTcFri | 0.001 | − 0.006 to 0.008 | 413.41 | 406.86 to 419.96 | < 0.001 |
| QTcFra | − 0.10 | − 0.017 to 0.003 | 423.42 | 416.98 to 429.87 | 0.003 |
| QTcH | 0.022 | 0.015 to 0.029 | 393.68 | 387.22 to 400.13 | 0.013 |
| QTcR | − 0.041 | − 0.048 to 0.034 | 460.42 | 453.98 to 466.87 | 0.043 |
| QTcD | − 0.034 | − 0.041 to − 0.027 | 448.99 | 442.41 to 455.58 | 0.029 |
| Female | |||||
| QTcB | − 0.069 | − 0.077 to − 0.061 | 495.97 | 489.30 to 502.64 | 0.066 |
| QTcFri | 0.016 | 0.008 to 0.024 | 410.71 | 404.01 to 417.40 | 0.004 |
| QTcFra | 0.019 | 0.012 to 0.027 | 408.09 | 401.86 to 414.31 | 0.006 |
| QTcH | 0.016 | 0.009 to 0.023 | 409.04 | 402.90 to 415.18 | 0.004 |
| QTcR | − 0.012 | − 0.020 to 0.004 | 439.20 | 432.82 to 445.58 | 0.002 |
| QTcD | − 0.023 | − 0.031 to − 0.015 | 450.40 | 443.82 to 456.99 | 0.008 |
QTc corrected QT interval, RR RR interval, 95% CI 95% confidence interval, ms milliseconds, Bazett’s correction formula (QTcB), Fridericia’s correction formula (QTcFri), Dmitrienko’s correction formula (QTcD), Framingham’s correction formula (QTcFra), Hodges’s correction formula (QTcH), Rautaharju’s correction formula (QTcR)
Fig. 1Comparison of linear regression slopes of different QTc formulas in both genders. A QTc/RR analysis in male, B QTc/RR analysis in females. QTc corrected QT interval, RR RR interval, Bazett’s correction formula (QTcB), Fridericia’s correction formula (QTcFri), Dmitrienko’s correction formula (QTcD), Framingham’s correction formula (QTcFra), Hodges’s correction formula (QTcH), Rautaharju’s correction formula (QTcR)
The normal limits of different QTc intervals in both genders
| QTc interval | LLN (ms) | 95% CI (ms) | ULN (ms) | 95% CI (ms) |
|---|---|---|---|---|
| Male n = 2028 | ||||
| QTcB | 379.13 | 377.09–381.12 | 458.92 | 455.36–462.28 |
| QTcFri | 378.85 | 376.12–380.13 | 448.84 | 446.23–450.88 |
| QTcFra | 377.81 | 375.54–380.00 | 448.00 | 445.33–450.00 |
| QTcH | 379.25 | 377.50–381.00 | 449.38 | 446.50–452.75 |
| QTcR | 384.49 | 382.47–386.47 | 456.63 | 453.97–459.56 |
| QTcD | 379.06 | 377.10–381.34 | 452.38 | 449.19–456.13 |
| Female n = 1924 | ||||
| QTcB | 398.21 | 396.19–400.28 | 476.84 | 473.43–480.36 |
| QTcFri | 386.09 | 383.45–389.04 | 457.64 | 454.20–461.65 |
| QTcFra | 387.80 | 386.09–390.67 | 456.08 | 452.52–458.67 |
| QTcH | 387.06 | 384.75–389.50 | 452.93 | 450.50–456.25 |
| QTcR | 394.69 | 391.64–396.49 | 460.66 | 456.84–465.00 |
| QTcD | 393.39 | 389.86–395.26 | 465.02 | 461.47–468.90 |
QTc corrected QT interval, LLN lower limit of normal, ULN upper limit of normal, 95% CI 95% confidence interval, ms milliseconds, Bazett’s correction formula (QTcB), Fridericia’s correction formula (QTcFri), Dmitrienko’s correction formula (QTcD), Framingham’s correction formula (QTcFra), Hodges’s correction formula (QTcH), Rautaharju’s correction formula (QTcR)
Sensitivity analysis of all-cause and cardiac mortality prediction by QTc > ULN in different QTc intervals in males
| QTc intervals | All-cause mortality | Cardiac mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|
| QTc > ULN (%) | Sens (%) | Spec (%) | NPV (%) | PPV (%) | Sens (%) | Spec (%) | NPV (%) | PPV (%) | |
| QTcB | 6.6 | 17.39 | 93.56 | 98.67 | 3.94 | 23.07 | 93.54 | 99.30 | 2.95 |
| QTcFri | 6.5 | 15.21 | 93.66 | 98.64 | 3.51 | 15.38 | 93.61 | 99.23 | 2.01 |
| QTcFra | 6.3 | 17.39 | 93.89 | 98.68 | 4.14 | 15.38 | 93.80 | 99.23 | 2.07 |
| QTcH | 6.2 | 10.86 | 93.83 | 98.57 | 2.60 | 11.53 | 93.80 | 99.20 | 1.56 |
| QTcR | 6.4 | 17.39 | 93.76 | 98.68 | 4.06 | 15.38 | 93.67 | 99.23 | 2.03 |
| QTcD | 6.5 | 17.39 | 93.66 | 98.67 | 4.00 | 15.38 | 93.57 | 99.23 | 2.00 |
ULN upper limit of normal, QTc corrected QT interval, Sens sensitivity, Spec specificity, PPV positive predictive value, and NPV negative predictive value, Bazett’s correction formula (QTcB), Fridericia’s correction formula (QTcFri), Dmitrienko’s correction formula (QTcD), Framingham’s correction formula (QTcFra), Hodges’s correction formula (QTcH), Rautaharju’s correction formula (QTcR)
Cox regression analysis of the un- and multivariate-adjusted model of all-cause and cardiac mortality prediction by QTc > ULN in different QTc intervals in males
| Unadjusted | Multivariate-adjusted | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All-cause mortality | Cardiac mortality | All-cause mortality | Cardiac mortality | |||||||||
| HR | 95%CI | HR | 95%CI | HR | 95%CI | HR | 95%CI | |||||
| QTcB | ||||||||||||
| QTcFri | 2.67 | 0.92–7.76 | 0.070 | 2.46 | 0.85–7.19 | 0.096 | ||||||
| QTcFra | 2.77 | 0.95–8.05 | 0.060 | 2.59 | 0.89–7.54 | 0.081 | ||||||
| QTcH | 1.84 | 0.73–4.67 | 0.195 | 1.97 | 0.59–6.59 | 0.266 | 1.92 | 0.75–4.90 | 0.171 | 2.08 | 0.62–6.99 | 0.236 |
| QTcR | 2.70 | 0.93–7.85 | 0.067 | 2.32 | 0.80–6.40 | 0.122 | ||||||
| QTcD | 2.66 | 0.91–7.72 | 0.072 | 2.09 | 0.71–6.10 | 0.179 | ||||||
ULN upper limit of normal, HR Hazard ratio, CI confidence interval, statistically significant HRs are bolded. QTc Corrected QT interval, Bazett’s correction formula (QTcB), Fridericia’s correction formula (QTcFri), Dmitrienko’s correction formula (QTcD), Framingham’s correction formula (QTcFra), Hodges’s correction formula (QTcH), Rautaharju’s correction formula (QTcR). Multivariate-adjust was done with age and heart rate